Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1
02:56pm, Tuesday, 10'th May 2022 Zacks Investment Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
10:20am, Tuesday, 10'th May 2022 Zacks Investment Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
10:20am, Friday, 06'th May 2022 Zacks Investment Research
Smart Beta ETF report for FBT
Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust
01:31pm, Thursday, 05'th May 2022 Zacks Investment Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.
Sarepta Therapeutics (SRPT) Q1 2022 Earnings Call Transcript
09:30am, Thursday, 05'th May 2022 The Motley Fool
SRPT earnings call for the period ending March 31, 2022.
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q1 2022 Results - Earnings Call Transcript
12:29am, Thursday, 05'th May 2022
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Dallan Murray - Senior Vice P
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
09:25pm, Wednesday, 04'th May 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 11.11% and 3.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
06:48pm, Wednesday, 04'th May 2022
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 11.11% and 3.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
12:30pm, Wednesday, 04'th May 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will p
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:23pm, Friday, 29'th Apr 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 29, 2022 tha
Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
04:49pm, Wednesday, 27'th Apr 2022
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022
12:30pm, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2022 financial re
Sarepta Therapeutics to Announce First Quarter 2022 Financial Results and Recent Corporate Developments on May 4, 2022
08:30am, Wednesday, 27'th Apr 2022
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2022 financial resu
Sarepta: The DMD Leader
05:05am, Tuesday, 26'th Apr 2022 Seeking Alpha
Sarepta is the unrivalled leader in the DMD or Duchenne Muscular Dystrophy space. Its revenue stream is growing tremendously over the years.
